Abeona Therapeutics Inc
Closed
5.72 1.24
Overview
Share price change
24h
Min
5.7
Max
5.79
Income | 3.4M -17M |
|---|---|
Sales | 3.3M 8.7M |
P/E Sector Avg | 5.822 49.712 |
Profit margin | -195.814 |
Employees | 226 |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +242.29% upside |
Next Earnings | 13 Aug 2026 |
|---|
Market Cap | -11M 272M |
|---|---|
Previous open | 4.48 |
Previous close | 5.72 |
Abeona Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
